Condition hub
Living with vasculitis
What vasculitis is, and why remission is the right word.
Inflammation in the vessel wall
This is inflammation in the walls of your blood vessels, and it covers a whole group of diseases sorted by which vessels they involve. What gets damaged follows from which vessels are inflamed, which is why two people with vasculitis can have almost nothing in common.
Remission, and not cure
Treatment gets most people with ANCA-associated vasculitis into remission, which means the disease is quiet and being held quiet. Cure would mean it was gone and nothing further was needed. Believing the second while the first is true is how people stop their medicine and relapse.
Giant cell arteritis is the urgent one
It can take vision for good within days, and normal inflammatory markers do not rule it out. In one group of patients with the diagnosis, close to one in six had a completely normal sedimentation rate and a completely normal CRP.1
The exercise evidence is one trial
Only one exercise trial exists in any form of vasculitis, and it is a small trial of resistance work in Takayasu arteritis that reports no figure anybody can quote. What applies to you instead is the steroid guideline, which covers every adult on a long course.2
The four-step plan, applied to vasculitis.
Get the right diagnosis
Which vessels are involved is what sorts these diseases, so the antibody tests, the urine and the imaging all do different jobs. A normal inflammatory marker settles nothing here, and least of all in giant cell arteritis.
Vasculitis and labs →Clean up your food
No diet has been tested against a control diet in any vasculitis. Eating well still does everything it does for anybody else, and a long steroid course makes your calcium and your vitamin D worth getting right.
Vasculitis and diet →Detox your daily life
Smoking, workplace dust and silica have been studied in other autoimmune diseases far more than in this one. Mention your work history anyway, because your lungs are reason enough to raise it.
Vasculitis and environment →Build a stronger body
The steroid guideline calls for weight-bearing and strength-building work, and it covers you if you are on a long course. That is the one sourced exercise instruction that reaches this group of diseases.
Vasculitis and exercise →
Pro tip
A new bad headache in anybody over fifty, jaw pain when chewing, a tender scalp, or any change in vision needs seeing the same day if giant cell arteritis is possible. Normal blood tests do not rule it out, and close to one patient in six with the diagnosis had both inflammatory markers completely normal in one series.
The vessels, sorted by size
The standard classification for these diseases sorts them by the size of vessel involved rather than by symptom, because vessel size predicts what a person will experience and how a doctor will treat it far better than any single symptom does. Large-vessel disease means giant cell arteritis and Takayasu arteritis, both of which attack the aorta and its major branches. Medium-vessel disease means polyarteritis nodosa and Kawasaki disease, which attack named arteries feeding organs like the kidneys and the gut.
Small-vessel disease splits into two families that look similar but behave differently underneath. One family is defined by antibodies called ANCA and includes granulomatosis with polyangiitis, microscopic polyangiitis, and eosinophilic granulomatosis with polyangiitis, which mainly reach the kidneys, lungs, sinuses, and nerves. The other family works through immune complexes instead, the same clumps of antibody and target that drive lupus, and includes IgA vasculitis and cryoglobulinemic vasculitis, which mainly reach the skin, kidneys, and joints.
That antibody split reflects a real biological difference rather than a naming convention. Fewer than a third of people with eosinophilic granulomatosis with polyangiitis test positive for ANCA at all, in a cohort of nearly four hundred patients followed for decades. The people who did test positive relapsed more often but died less often than the people who didn't, so the antibody marks a genuine fork in how the disease behaves rather than a label attached to some patients and not others.
Remission, and why the word counts
Remission means the disease is quiet and is being held quiet. In most cases that rests on treatment continuing, and in every case it rests on your tests continuing, because the disease comes back often enough to expect it. Cure would mean it's gone and neither of those was needed any more.
Anyone calling these diseases curable might lead you to stop your medicine, which is the harm the distinction exists to prevent. A relapse in ANCA-associated vasculitis can cost you kidney function, and a relapse in giant cell arteritis can cost you sight. Neither of those losses comes back once it has happened.
Giant cell arteritis, which is urgent
Its clock runs differently from everything else here, because it can take vision for good within days, so it has to be recognized within hours rather than weeks. Four symptoms should be acted on in anyone over fifty, which are a new bad headache, jaw pain when chewing, a tender scalp, and any change in vision. Sudden loss of vision in one eye needs help today, from whoever is nearest.
Timing is part of it as well. People tested longer after their symptoms began were more likely to have normal markers, not less, which is the opposite of what most people assume about waiting. So symptoms lead here and the tests follow.
Why the tests continue
Common misconceptions.
Myth. Vasculitis is rare, so it doesn't apply to me.
Reality. A 30-year population study in the UK put the overall incidence of ANCA-associated vasculitis at 25.1 per million person-years, a real but genuinely uncommon rate. Giant cell arteritis is far more common than that on its own, concentrated almost entirely in people over fifty. Uncommon is not the same as invisible, and missing one of these diseases can cost a kidney or a person's sight.
In plain words. These diseases are uncommon rather than common. ANCA vasculitis runs about 25 cases per million people each year. Giant cell arteritis is more common, mostly in people over fifty. Rare doesn't mean it can be ignored.
Myth. Vasculitis is fatal without aggressive treatment.
Reality. The trial that established rituximab as a standard treatment for ANCA-associated vasculitis found 64 percent of patients reached remission without steroids at six months, against 53 percent on the older cyclophosphamide regimen, and rituximab did better still in people whose disease had already relapsed once. Neither drug cures the disease, and both changed what happens after diagnosis a great deal compared with having no effective treatment at all.
In plain words. Modern treatment changes the outlook a lot. About two-thirds of patients reach remission on rituximab within six months. Neither drug is a cure, but going untreated and being treated are very different situations.
Myth. A negative ANCA test rules out vasculitis.
Reality. In one of the largest cohorts of eosinophilic granulomatosis with polyangiitis ever assembled, fewer than a third of patients, 31 percent, tested positive for ANCA at diagnosis. The rest had the disease confirmed by their symptoms, their biopsy, and their imaging rather than by the antibody. A negative ANCA narrows the picture. It doesn't close the case.
In plain words. Not every type of vasculitis produces a positive ANCA test. In one large study, fewer than a third of one type tested positive. Biopsy and imaging still count when the antibody is negative.
When to see a rheumatologist.
See a rheumatologist if you have:
- New headache in someone over 50, especially with jaw claudication or vision changes
- Hematuria with elevated creatinine, especially with respiratory symptoms
- Recurrent sinusitis, nasal crusting, or saddle-nose deformity
- Mononeuritis multiplex (multiple peripheral nerves affected)
- Palpable purpura on the legs
- Unexplained constitutional symptoms (fever, weight loss, fatigue) plus organ-specific findings
- Asthma plus eosinophilia plus systemic symptoms (suggestive of EGPA)
Giant cell arteritis is the one on this list that can cost you sight within days, so a new headache over fifty with jaw or vision symptoms is a same-day problem. Everything else here is a prompt referral instead of an emergency, and the chance of relapse is why your tests continue long after you feel well.
References.
- Currier C; Bays A; Thomason J. Normal inflammatory markers in giant cell arteritis: a diagnostic blind spot. Rheumatology International. 2025;45. 10.1007/s00296-025-05930-3Retrospective diagnostic accuracy study within a single fast-track GCA clinic
- Li G; Liu F; Wang Y et al. Effects of resistance exercise on treatment outcome and laboratory parameters of Takayasu arteritis with magnetic resonance imaging diagnosis: A randomized parallel controlled clinical trial. Clinical Cardiology. 2020;43:1273-1278. 10.1002/clc.23439Randomised parallel controlled clinical trial
- Buckley L; Guyatt G; Fink H et al. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid‐Induced Osteoporosis. Arthritis & Rheumatology. 2017;69:1521-1537. 10.1002/art.40137GRADE-based clinical practice guideline
- Jennette JC; Falk RJ; Bacon PA et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis & Rheumatism. 2013;65:1-11. 10.1002/art.37715International consensus nomenclature and classification scheme for the vasculitides
- Mukhtyar CB; Ashurst K; Coath FL et al. Changing incidence and serotype trends in ANCA-associated vasculitis: a 30-year population-based study in Norfolk, UK. Rheumatology (Oxford). 2026;65:keag325. 10.1093/rheumatology/keag32530-year population-based incidence study
- Stone JH; Merkel PA; Spiera R et al. Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis. New England Journal of Medicine. 2010;363:221-232. 10.1056/NEJMoa0909905Phase 2/3 multicenter
- Comarmond C; Pagnoux C; Khellaf M et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis & Rheumatism. 2013;65:270-281. 10.1002/art.37721Retrospective cohort
This page gathers the published research on this subject into one place. The studies behind it were published between 1989 and 2026, and every figure links to the paper it came from. Those studies were peer reviewed. This summary of them was not. Dr. Sarah Luebker is reviewing these pages one at a time and has not reached this one yet, so it carries no medical review date and nothing here is her opinion or her advice to you. Each page gets updated as she reaches it. It is here in the meantime because the science is worth having in one organized place that is easy to find and easy to read. Talk to your own clinician before acting on any of it.